Automate Your Wheel Strategy on QURE
With Tiblio's Option Bot, you can configure your own wheel strategy including QURE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
This biotech's stock is soaring after a ‘polarizing' FDA official is stepping down
Published: March 09, 2026 by: Market Watch
Sentiment: Positive
Vinay Prasad, an official for the Food and Drug Administration, is reportedly stepping down, which is welcome news for biotech companies.
Read More
This biotech's stock is soaring after a ‘polarizing' FDA official is stepping down
Published: March 09, 2026 by: Market Watch
Sentiment: Positive
Vinay Prasad, an official for the Food and Drug Administration, is reportedly stepping down, which is welcome news for biotech companies.
Read More
QURE Stock Crashes 32% in a Week: Here's What You Should Know
Published: March 06, 2026 by: Zacks Investment Research
Sentiment: Negative
uniQure stock plunges 32% in a week after the FDA says AMT-130 phase I/II Huntington's disease data are not sufficient as primary evidence for a potential marketing application.
Read More
uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline
Published: March 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025?
Read More
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
Published: March 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, March 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. (“uniQure” or “the Company”) (NASDAQ: QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Read More
Holzer & Holzer, LLC Reminds QURE Investors of the April 13, 2026 Lead Plaintiff Deadline in the uniQure N.V. Securities Class Action
Published: March 05, 2026 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, March 05, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding uniQure's business, operations, and prospects, including allegations that: (1) the design of uniQure's Pivotal Study—including comparison of the Pivotal Study results to the ENROLL-HD external historical data set—was not fully approved by the FDA; and (2) Defendants downplayed the likelihood that, despite purportedly highly successful results from the Pivotal Study, uniQure would have to delay its Biologics License …
Read More
FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington's disease
Published: March 05, 2026 by: CNBC
Sentiment: Negative
UniQure needs to run another study to prove its gene therapy "actually helps people with Huntington's disease," a senior FDA official said. The official said UniQure is the "latest company to make a failed therapy for Huntington's patients.
Read More
Sr. FDA official calls Uniqure's Huntington's disease treatment a failure
Published: March 05, 2026 by: Reuters
Sentiment: Negative
A senior FDA official called Uniqure's experimental Huntington's disease treatment a "failed product" in a conference call with media members on Thursday, casting further doubt on the prospects of its experimental gene therapy.
Read More
uniQure (QURE) Loses 67.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Published: March 04, 2026 by: Zacks Investment Research
Sentiment: Negative
The heavy selling pressure might have exhausted for uniQure (QURE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read More
SHAREHOLDER ALERT: Berger Montague Reminds UniQure N.V. (QURE) Investors of Class Action Lawsuit Deadline
Published: March 04, 2026 by: Newsfile Corp
Sentiment: Neutral
Philadelphia, Pennsylvania--(Newsfile Corp. - March 4, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against uniQure N.V. (NASDAQ: QURE) ("uniQure" or the "Company") on behalf of investors who purchased or otherwise acquired uniQure securities during the period from September 24, 2025 through October 31, 2025 (the "Class Period").
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines – QURE
Published: March 03, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
Published: March 03, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, March 03, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. (“uniQure” or “the Company”) (NASDAQ: QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Read More
$QURE ALERT: uniQure N.V. Sued for Securities Law Violations; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
Published: March 02, 2026 by: GlobeNewsWire
Sentiment: Neutral
Block & Leviton announces a securities fraud lawsuit has been filed against uniQure (Nasdaq: $QURE). Investors who lost money should contact the firm.
Read More
uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face March 13, 2026, Deadline
Published: March 02, 2026 by: PRNewsWire
Sentiment: Neutral
Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? Affected uniQure N.V.
Read More
QURE CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
Published: March 02, 2026 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In uniQure To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in uniQure between September 24, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - March 2, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against uniQure N.V.
Read More
uniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
Published: March 02, 2026 by: Zacks Investment Research
Sentiment: Negative
uniQure (QURE) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to a loss of $1.5 per share a year ago.
Read More
uniQure: Shares Tumble On Fresh FDA Controversy - What Investors Should Know
Published: February 27, 2026 by: Seeking Alpha
Sentiment: Negative
uniQure N.V. shares plunged >30% after FDA Commissioner comments were interpreted as negative for AMT-130, its Huntington's gene therapy candidate. QURE's AMT-130 showed statistically significant slowing of disease progression at 36 months, but FDA now questions the adequacy of external control data for approval. Regulatory uncertainty remains high, with no clear timeline for BLA submission; QURE holds $597m cash and a $1bn market cap, supporting ongoing R&D and potential EU strategy.
Read More
uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE
Published: February 27, 2026 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 27, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against uniQure N.V. ("uniQure " or "the Company") (NASDAQ: QURE ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Read More
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
Published: February 27, 2026 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 27, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Read More
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QURE
Published: February 26, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - February 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE
Published: February 26, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE).
Read More
QURE INVESTOR ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
Published: February 26, 2026 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In uniQure To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in uniQure between September 24, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against uniQure N.V.
Read More
Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm
Published: February 26, 2026 by: GlobeNewsWire
Sentiment: Neutral
New class action for uniQure (QURE) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of Apr. 13, 2026.
Read More
Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. Investors
Published: February 26, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises UniQure N.V., (“uniQure” or the "Company") (NASDAQ: QURE) investors of a class action on behalf of investors that bought securities between September 24, 2025 and October 31, 2025, inclusive (the “Class Period”). uniQure investors have until April 13, 2026 to file a lead plaintiff motion.
Read More
uniQure N.V. Stock Alert: QURE Stockholders Who Lost Money in the Company Should Contact Robbins LLP for Information on How to Recover Their Losses
Published: February 26, 2026 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025.
Read More
INVESTOR REMINDER: Berger Montague Notifies uniQure N.V. (QURE) Investors of a Class Action Lawsuit and Deadline
Published: February 26, 2026 by: Newsfile Corp
Sentiment: Neutral
Philadelphia, Pennsylvania--(Newsfile Corp. - February 26, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against uniQure N.V. (NASDAQ: QURE) ("uniQure" or the "Company") on behalf of investors who purchased or otherwise acquired uniQure securities during the period from September 24, 2025 through October 31, 2025 (the "Class Period").
Read More
uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline
Published: February 25, 2026 by: GlobeNewsWire
Sentiment: Neutral
Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? Affected uniQure N.V.
Read More
NASDAQ: QURE INVESTOR ALERT: Berger Montague Advises uniQure N.V. (NASDAQ: QURE) Investors of an April 13, 2026 Deadline
Published: February 23, 2026 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA, Feb. 23, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against uniQure N.V. (NASDAQ: QURE) ("uniQure" or the "Company") on behalf of investors who purchased or otherwise acquired uniQure securities during the period from September 24, 2025 through October 31, 2025 (the "Class Period").
Read More
uniQure to Announce 2025 Financial Results
Published: February 23, 2026 by: GlobeNewsWire
Sentiment: Neutral
~ uniQure to host earnings call on Monday, March 2, 2026 at 8:00 a.m. ET ~ ~ uniQure to host earnings call on Monday, March 2, 2026 at 8:00 a.m. ET ~
Read More
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
Published: February 23, 2026 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 23, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Read More
About uniQure N.V. (QURE)
- IPO Date 2014-02-05
- Website https://www.uniqure.com
- Industry Biotechnology
- CEO Matthew Craig Kapusta
- Employees 209